N	Concordance
1	rugs tested included doxorubicin (ADR), cisplatin (DDP) and dacarbazine (DTIC). 
2	viability and clonogenic survival after cisplatin treatment. Further experiments
3	 tropisetron was less effective against cisplatin-induced emesis in females. The
4	o determine whether the cytotoxic agent cisplatin (CDDP), also known as a radios
5	otherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP) is a serious problem in
6	ting extremely high-dose intra-arterial cisplatin therapy with systemic sodium t
7	onuclei in Schwann cells was induced by cisplatin at the dosis about 20 times lo
8	nuous 5-FU infusion plus low-dose daily cisplatin may become clinically useful a
9	f induction chemotherapy with high-dose cisplatin and vinblastine followed by la
10	                    (5-FU) and low-dose cisplatin (CDDP) for 4 weeks. Of the tot
11	 number of progeny. The anticancer drug cisplatin, which causes DNA strand break
12	treated with anticancer drugs including cisplatin (CDDP) at 50 mg/m2 or more. Th
13	 in the group receiving intraperitoneal cisplatin (49 months; 95 percent confide
14	S tumors, conventional-dose intravenous cisplatin-based chemotherapy regimens ar
15	he efficacy and toxicity of neoadjuvant cisplatin/fluorouracil  (CDDP/5-FU) foll
16	day continuous intravenous infusions of cisplatin (20 mg/m2/day) and 5-fluoroura
17	mbination chemotherapy: three cycles of cisplatin and etoposide and six cycles o
18	ody surface area, and administration of cisplatin over 2-5 days per course vs 1 
19	ors resulting in SKOV3/cp resistance to cisplatin are the reduction of intracell
20	 objective response rate to vinorelbine/cisplatin (VNB/CDDP)  in patients with m